Influenza A virus-specific B lymphocytes and the antibodies they produce protect against infection 1 . However, the outcome of interactions between an influenza haemagglutinin-specific B cell via its receptor (BCR) and virus is unclear. Through somatic cell nuclear transfer we generated mice that harbour B cells with a BCR specific for the haemagglutinin of influenza A/WSN/33 virus (FluBI mice). Their B cells secrete an immunoglobulin gamma 2b that neutralizes infectious virus. Whereas B cells from FluBI and control mice bind equivalent amounts of virus through interaction of haemagglutinin with surface-disposed sialic acids, the A/WSN/33 virus infects only the haemagglutinin-specific B cells. Mere binding of virus is not sufficient for infection of B cells: this requires interactions of the BCR with haemagglutinin, causing both disruption of antibody secretion and FluBI B-cell death within 18 h. In mice infected with A/WSN/33, lung-resident FluBI B cells are infected by the virus, thus delaying the onset of protective antibody release into the lungs, whereas FluBI cells in the draining lymph node are not infected and proliferate. We propose that influenza targets and kills influenza-specific B cells in the lung, thus allowing the virus to gain purchase before the initiation of an effective adaptive response.
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Memory B lymphocytes contribute to the protective immune response to flu infection by producing immunoglobulins that bind and neutralize the virus 1 . The lung of an exposed individual contains influenza-specific memory B cells that bind virus, differentiate into plasma cells and secrete either immunoglobulin G (IgG) or IgA locally, reducing the spread of virus 2, 3 . However, the fate of virus-specific B cells that encounter live influenza virus remains unknown.
The low frequency of antigen-specific B cells has hampered analysis of the interactions between live virus, flu antigens and the primary B cells specific for them 2 . To detect influenza-virus-specific B cells, we used sortase-mediated labelling to install Alexa 647 fluorophore onto the haemagglutinin (HA) protein [4] [5] [6] . Virus was disrupted with detergent, HA-Alexa 647 was purified by immunoprecipitation and dialysed to form fluorescent flu micelles (Extended Data Fig. 1a-d) . These flu micelles did not stain splenocytes from uninfected mice, but did stain a small number of CD19 1 cells in spleens of mice infected with influenza and boosted multiple times with A/WSN/33 in incomplete Freund's adjuvant (Extended Data Fig. 1e ).
Virus-specific CD19 1 B cells, isolated by fluorescence-activated cell sorting ( Fig. 1a) , were used as a source of nuclei for somatic cell nuclear transfer [7] [8] [9] . We transferred the nuclei of these B cells into enucleated oocytes and derived embryonic stem cells 7-9 that harbour the VDJ/VJ (heavy chain/light chain) rearrangements of the original donor B cell to produce chimaeric mice. We screened offspring of the founder chimaeras by ELISA for the presence of anti-flu antibodies and obtained one animal that showed high titres of IgG2b flu-specific antibodies (Extended Data Fig. 2 ) and IgG2b 1 IgM 2 B cells in the absence of infection ( Fig. 1b ). We backcrossed this mouse to C57BL/6 to secure germline transmission of the VDJ/VJ pair and hereafter refer to the line as FluBI. We know of no other mouse model that harbours B cells of known pathogen specificity or whose primary B cells produce IgG2b.
The sequences of the rearranged heavy and light chain genes (Extended Data Fig. 3 ) show 7 and 4 somatic mutations in the V H and Vk segments, respectively. We established the specificity of the FluBI IgG2b antibody *These authors contributed equally to this work. 1 by immunoprecipitation from lysates of [ 35 S]cysteine/methioninelabelled, A/WSN/33-infected MDCK cells (Fig. 1c ). The antibody retrieves HA0 and its cleavage products 10 HA1 and HA2. FluBI IgG2b antibody purified from hybridomas generated from FluBI;Rag2 2/2 splenocytes gave similar results (Methods). The serum from FluBI mice neutralizes A/WSN/33 in vitro ( Fig. 1d ) and in vivo ( Fig. 1e ). Cytofluorometry of B-cell populations in lymph node, spleen and bone marrow from FluBI mice showed a complete absence of B-1a B cells, and other B-cell subsets were near-normal in distribution and number (Extended Data Fig. 4 ). As shown for OBI mice 7 , the presence of a functionally rearranged c2b heavy chain locus does not compromise B-cell development, despite the deletion of the m, d, c3 and c1 constant regions in FluBI mice.
To determine the fate of HA-specific B cells upon encounter with virus, we obtained B cells from the FluBI mouse and from OBI mice, whose B cells produce an IgG1 specific for ovalbumin 7 . Before infection, we activated cells overnight with anti-CD40 to improve biosynthetic labelling, used to assess viral antigen synthesis. At 2 h post infection (h.p.i.) FluBI B cells infected with A/WSN/33 synthesize vastly more HA, nucleoprotein (NP) and M2 protein (inset) than OBI B cells ( Fig. 2a ). In FluBI B cells, the levels of NP were comparable to those obtained from A/WSN/33-infected MDCK cells, an indication that replication of A/WSN/33 in FluBI B cells is robust ( Fig. 2a and Extended Data Fig. 5 ). Neither FluBI nor OBI B cells were infected by the closely related strain A/Puerto Rico/8/1934 (H1N1) or with A/Udorn/307/1972 (H3N2) ( Fig. 2b and Extended Data Figs 6, 7) .
The increased levels of antigen detected in FluBI B cells might result from improved binding of virus via BCR-HA interactions. To measure virus binding, we incubated anti-CD40-activated B cells with sortasemodifiable (HA-SRT) Alexa 647-labelled virus (HA-SRT Alexa 647 ) 4 and measured bound virus by cytofluorometry. Virus bound equally well to FluBI and OBI B cells ( Fig. 2c ). To determine whether increased susceptibility of FluBI B cells to infection is indeed BCR-dependent, we generated HA-SRT virus, transacylated 4 at the carboxy terminus of HA1 with a synthetic 17-residue ovalbumin peptide that comprises the epitope recognized by the ovalbumin-specific OBI B cells (HA-SRT wtOBI ). This virus should now also bind to the BCR expressed on the surface of OBI B cells. For comparison we labelled HA-SRT virus with a mutant version of the OBI 17-mer peptide (HA-SRT mtOBI ) no longer recognized by the OBI IgG1. We then exposed FluBI and OBI B cells to either HA-SRT wtOBI or HA-SRT mtOBI virus ( Fig. 2d ). As expected, the two HA-SRT viruses infected FluBI B cells equally, regardless of the identity of the peptide epitope installed. In contrast, only HA-SRT wtOBI infected OBI B cells. The level of infection in OBI B cells exposed to HA-SRT wtOBI was similar to that seen in FluBI B cells. The presence of a BCR that recognizes HA, native or modified to impart BCR reactivity, thus causes susceptibility to influenza infection. Mere adsorption of virus to the cell surface through interactions with sialic acids may therefore not suffice to gain entry [11] [12] [13] , and interaction with an internalizing receptor is important [14] [15] [16] [17] . Antigen-occupied BCRs are indeed efficiently internalized 18 , especially when engaged by a multivalent ligand, and could thus improve virus entry and infection.
Do infected B cells produce virus or virus-like particles (VLPs)?
We infected OBI and FluBI B cells with A/WSN/33 and biosynthetically labelled them 4-6 h.p.i. We incubated the culture supernatants with chicken erythrocytes to recover released virus and VLPs via interactions of HA with erythrocyte-borne sialic acids, and analysed adsorbed materials by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography to detect the presence of viral structural proteins ( Fig. 2e ). NP and M1 proteins were present in material released by FluBI but not OBI B cells, indicating that infection of FluBI B cells was productive.
We also looked for secreted antibody from A/WSN/33-exposed B cells ( Fig. 3a) . OBI cells showed no change in their ability to secrete 
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antibody after exposure to A/WSN/33, presumably because they are poorly infected, if at all. Not only did FluBI B cells exposed to A/WSN/33 show decreased levels of secreted IgG2b, they also died within 18 h.p.i. (Fig. 3b ) under conditions where OBI B cells survived.
To explore the consequences of in vivo exposure of FluBI cells to virus and track FluBI B cells, we transferred Celltrace violet-marked OBI (IgG1 1 ) and FluBI (IgG1 2 ) B cells, obtained from transnuclear animals crossed onto the GFP-tagged major histocompatibility complex class II (MHCII-GFP) background, into naive recipients. The number of B cells transferred was chosen such that it still allowed detection of transferred cells in lungs and mediastinal lymph nodes from infected mice. Mice were inoculated intranasally with live or irradiated A/WSN/33 and mixed with ovalbumin to ensure engagement of the respective donor BCRs. We then measured cell number, proliferation and expression of viral antigens on donor MHCII-GFP 1 B cells (Fig. 4) . The ovalbumin-specific OBI B cells showed robust proliferation in both spleen and mediastinal lymph nodes, whereas FluBI B cells proliferated to a greater extent in the mediastinal lymph nodes in response to live virus, probably owing to the increased amount of antigen present locally following viral replication in the lungs. By day 6 post-infection, proliferating FluBI B cells in the lymph nodes had differentiated into CD138 1 plasmablasts (Extended Data Fig. 8 ). Mice that received irradiated A/WSN/33 showed less proliferation of FluBI cells in mediastinal lymph nodes owing to the absence of antigen synthesis, but more proliferation of FluBI cells in the lungs at 3 days post-infection than animals that received live virus ( Fig. 4a ; day 3 lungs live 2.7 6 0.43% n 5 6 versus day 3 lungs irradiated 6.5 6 1.3% n 5 5; P 5 0.015).
To detect intracellular influenza viral proteins as an additional measure of infection, we generated HA-and NP-specific heavy-chainonly antibody fragments (VHHs) from an influenza-immunized alpaca (Extended Data Fig. 9 ). These small, single-domain VHHs are C-terminally modified with an LPETG motif for direct coupling with TAMRA using sortase 19 and detect flu antigens in FluBI B cells infected in vitro (Extended Data Fig. 10 ). In mice infected with live A/WSN/33 we observed HA-and NP-positive, infected FluBI cells in the lung (Fig. 4b, c) . Although virus is reportedly delivered to the mediastinal lymph nodes by dendritic cells 20, 21 , no flu-antigen-positive B cells were found in the mediastinal lymph nodes (Fig. 4b ). Not unexpectedly, mice exposed to irradiated A/WSN/33 lacked flu-antigen-positive B cells in either location. Co-transferred OBI cells were present in the lungs of infected mice, but were HA-and NP-negative.
To determine whether infection of lung-resident flu-specific B cells affects antibody production in vivo, we measured in bronchoalveolar lavage (BAL) fluid the presence of flu-specific IgG2b, secreted by the transferred FluBI B cells, and found that irradiated virus elicited a 
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stronger and more rapid initial response than live virus, consistent with the ability of live, but not irradiated virus to kill FluBI B cells. Serum levels of flu-specific IgG2b were equivalent in mice receiving live versus irradiated virus, indicating that loss of flu-specific IgG2b is restricted to the lung bronchoalveolar space. FluBI cells, specific for haemagglutinin and secreting a neutralizing antibody, themselves succumb to infection mediated by the surfacedisposed BCR. The rapid death of A/WSN/33-specific FluBI cells provides respite for the virus at the lung epithelium, a site to which antigen-specific B cells are recruited in the course of infection and where they remain as sentinels thereafter 2, 22, 23 . Infection and killing of a fraction of the rare antigen-specific B cells impairs the kinetics of the memory response, and confers an advantage to the virus with its replication cycle measured in hours. The ability of a pathogen to exploit this mode of entry and eliminate the initial wave of the very B cells capable of counteracting the infection is an efficient means of ensuring a window for replication and horizontal transmission. It is unlikely to be limited to influenza virus.
METHODS SUMMARY
Sortase labelling. HA-SRT virus (a derivative of A/WSN/33, ref. 6) was incubated with Sortase A (150 mM) and the indicated nucleophile (500 mM) in sortase labelling buffer with 0.2% BSA at 37 uC for 1 h, resulting in site-specific labelling of HA on the intact virus particle. Labelled virus was concentrated over a 20% sucrose cushion. For flu micelles, HA-SRT Alexa 647 was disrupted with detergent, immunoprecipitated with anti-Alexa 647 and dialysed to form HA-enriched micelles. For OBI epitope labelling, HA-SRT was labelled with OBI (GGGFDKLPGFGDSI EAQGGK) or OBI* (GGGFDKLPGAGASIEAQGGK). Hybridoma production. FluBI;Rag2 2/2 spleen cells were fused with NS-1 cells. The resulting hybridomas were screened for A/WSN/33 reactivity by ELISA using horseradish peroxidase-coupled anti-IgG2b.
METHODS
Reagents. Anti A/WSN/33 serum was generated by infecting BALB/C mice with A/WSN/33 (2 3 10 5 p.f.u. per mouse). Anti-M2 antibody (14C2) was purchased from Santa Cruz Biotechnology. OBI peptides were provided by the MIT biopolymers facility. The amino acid sequence that comprises the OBI epitope is as follows: GGGFDKLPGFGDSIEAQGGK. The mutant sequence that fails to bind to the OBI antibody is as follows (substitutions denoted in bold): GGGFDKLPG AGASIEAQGGK. Sortase was expressed in Escherichia coli and purified as described 24 . The GGGK-Alexa 647 peptide used to label HA-SRT was provided by M. Witte. Anti IgG-FITC antibody (A1101) was purchased from Molecular Probes. Chicken erythrocytes (cRBCs) were purchased from Lampire Biological Laboratories. Express 35 S protein labelling mix was purchased from Perkin Elmer. Methionine and cysteine-free RPMI, Optimem, HEPES buffer and non-essential amino acids (NEAA) were purchased from Life Technologies. Endoglycosidase H (EndoH) and PNGase F were purchased from New England Biolabs. Protein-G agarose and EDTA-free complete protease inhibitor cocktail was purchased from Roche Diagnostics. Virus propagation and infection. A/Puerto Rico/8/1934 (H1N1) and A/Udorn/ 307/1972 (H3N2) viral stocks were a gift from X. Zhuang. MDCK cells and RAW cells were originally obtained from the ATCC, and are tested for mycoplasma every 3-6 months. A/WSN/33 and HA-SRT virus 4 were propagated in MDCK cells grown in Optimem and supplemented with 1 mg ml 21 L-1-tosylamido-2phenylethyl chloromethyl ketone (TPCK) -treated trypsin. Titres of A/WSN/33 and HA-SRT virus stocks were determined by plaque assay on MDCK cells. For the plaque assay, MDCK cells were cultured in 24-well dishes until sub-confluent. Cells were washed twice in PBS supplemented with Ca 21 and Mg 21 (PBS1) and infected with tenfold serial dilutions of virus in PBS1 supplemented with 0.25% BSA for 1 h at room temperature. Cells were washed once in PBS1 then overlaid with plaque media (13MEM, 0.25% BSA, 0.8% agar, 0.5 mg ml 21 trypsin-TPCK) and placed at 37 uC. After 24 to 48 h, the agar overlay was removed and the cells were fixed with 3% paraformaldehyde and permeabilized using PBS 0.5% NP-40. Influenza plaques were stained using monoclonal antibody against NP conjugated to FITC then visualized and quantified by fluorescent microscopy. Labelled HA-SRT virus was quantified using haemagglutination assay against a standard containing a known quantity of A/WSN/33. For all in vitro experimental infections virus was diluted in PBS1/BSA(0.25%) and supplemented with 1 mg ml 21 TPCKtreated trypsin. In the case of MDCK cells, cells were trypsinized and infections carried out in suspension. Virus and cells were incubated on ice for 30 min. Cells were washed with PBS1, and resuspended in DMEM with 0.2% BSA, 100 mM HEPES and NEAA (or RPMI with 0.2% BSA, 100 mM HEPES and NEAA in experiments where B cells were used). Sortase labelling of HA-SRT virus. HA-SRT virus 4 was incubated with sortase A (150 mM) and the indicated nucleophile (500 mM) in sortase labelling buffer (100 mM Tris pH 7.4, 150 mM NaCl, 10 mM Ca 21 ) supplemented with 0.2% BSA at 37 uC for 1 h. The labelled virus was then concentrated over a 20% sucrose cushion and resuspended in sortase labelling buffer supplemented with 0.2% BSA. Neutralization assay. 10 5 p.f.u. A/WSN/33 was incubated with 20 ml of the indicated test serum for 30 min on ice. The virus/serum mixture was then overlaid onto 10 6 MDCK or RAW macrophages and incubated for 30 min at room temperature. Cells were washed and incubated at 37 uC in DMEM (0.2% BSA). At 2 h.p.i., both cell types were biosynthetically labelled for two hours and subsequently lysed. Immunoprecipitates were prepared with anti-WSN serum and analysed by SDS-PAGE and autoradiography. Animal care. All mice were housed at the Whitehead Institute for Biomedical Research and were maintained according to protocols approved by the MIT Committee on Animal Care. A/WSN/33-infected animals were housed in an approved quarantine room at Whitehead Institute. C57BL/6 and BALB/c mice were purchased from Jackson Labs. Rag2 2/2 mice (RAGTN12) were purchased from Taconic. MHCII-GFP mice 25 and OBI mice 7 have been described previously. In vivo influenza infections. 8-10 week old male mice were anesthetized by a single dose of avertin (1.25% tribromoethanol, GIBCO), 250 mg kg 21 body weight, delivered by intraperitoneal injection. A/WSN/33 (2 3 10 5 p.f.u. per mouse unless otherwise stated) or A/Puerto Rico/8/1934 (2 3 10 5 p.f.u.) was administered intranasally. Infected BALB/c mice were weighed daily, and mice losing more than 20% of starting weight were euthanized. Infected C57BL/6 mice are intrinsically more resistant to influenza infection 26 , and did not show more than 5% weight loss; C57BL/6 mice used as hosts for adoptive transfer (intravenously) of FluBI or OBI B cells were infected with A/WSN/33 within 24 h of donor cell transfer. Mice that received adoptive transfer of FluBI and/or OBI B cells were allowed to intermix freely in a large cage before separating mice into groups to receive irradiated or live flu virus. Infections were performed by a non-blinded investigator. Successfully administration of intranasal virus was verified by recruitment of FluBI cells to the MSLN. ,5% of mice showed failure of intranasal delivery and were excluded from analysis, as per pre-established criteria. Transnuclear mouse generation. Transnuclear mice were generated as previously described [7] [8] [9] 27, 28 . Briefly, flu-specific B cells were sorted by FACS and used as a source of donor nuclei for somatic cell nuclear transfer according to the protocol established by the Wakayama group 29 . The mitotic spindle was removed from mouse oocytes and replaced with donor nuclei. The nucleus-transplanted oocytes were then activated in medium containing strontium and trichostatin A, and allowed to develop in culture to the blastocyst stage. Because the live birth rate of somatic cell nuclear transfer blastocysts transferred into pseudopregnant females is quite low, somatic cell nuclear transfer blastocysts were used instead to derive embryonic stem (ES) cell lines. These ES cell lines were then injected into wild type B6xDBA F1 blastocysts and implanted into pseudopregnant females. The resulting chimaeric pups were mated to C57BL/6 females to establish the FluBI line. All animals used were backcrossed 4-5 generations onto C57BL/6 or C57BL/6;Rag2 2/2 backgrounds. Flu micelles. HA-SRT virus was incubated with Sortase A (150 mM) and Alexa 647 nucleophile (500 mM) in sortase labelling buffer (100 mM Tris pH 7.4, 150 mM NaCl, 10 mM Ca 21 ) supplemented with 0.2% BSA at 37 uC for 1 h. HA-SRT Alexa 647 virus was disrupted with Triton X100 and incubated with 400 mg anti-Alexa 647 overnight. HA-Alexa 647 was then recovered using protein G-Sepharose. Bound proteins were eluted with 0.1 M glycine pH 2.8. Detergent was dialysed to form protein micelles 30 . Flow cytometry. Cells were collected from spleen, pooled mesenteric and cervical lymph nodes, mediastinal lymph nodes, lung, peritoneal cavity and bone marrow. Lung tissue was digested in RPMI with 1% (w/v) collagenase D (Sigma) for 30-60 min at 37 uC before mechanical dissociation with a 40-mm cell strainer. Cell preparations were subjected to hypotonic lysis to remove erythrocytes, stained and analysed using a FACS Fortessa (BD). Celltrace violet was purchased from Invitrogen. All antibodies were from BD Pharmingen. For intracellular staining, cells were fixed and permeabilized using Cytofix/Cytoperm (BD) according to the manufacturer's instructions. Flu-specific ELISAs. High-binding 96-well microtitre plates (Costar) were coated overnight at 4 uC with A/WSN/33 (2 3 10 4 p.f.u. ml 21 ) in PBS. Plates were washed 3 times with wash buffer (PBS, 0.05% Tween-20), blocked with 10% fetal bovine serum for 1 h at room temperature, washed 3 times, and incubated with samples. Bronchoalveolar lavage (BAL) fluid samples were collected by inserting a 24 gauge catheter into an incision in the trachea, filling the lungs with 1 ml PBS and recovering 0.7-0.8 ml of lavage fluid. BAL fluid samples were used neat. Serum samples were used at 1:10 dilution. FluBI antibody purified from hybridoma supernatants was used as standard. Plates were incubated with samples at room temperature for 2 h, washed 5 times, and incubated with HRP-coupled anti-IgG2b secondary reagent for 1 h. Plates were washed 7 times, and detected using 3,39,5,59-tetramethylbenzidine (TMB) liquid substrate (Sigma). Cell culture. B cells were purified from pooled spleen and lymph nodes by negative selection using anti-CD43 magnetic beads (Miltenyi Biotec). B cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 100 U ml 21 penicillin G sodium, 100 mg ml 21 streptomycin sulphate, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, and 0.1 mM 2-mercaptoethanol. For differentiation of B cells into plasmablasts, anti-CD40 (BD clone HM40-3, 1 mg ml 21 ) was added to the culture medium. MDCK cells and RAW macrophages were cultured in DMEM supplemented with 10%FCS, 100 mM HEPES and NEAA. For experiments where B cells and MDCK cells were compared side by side, MDCK cells were cultured during the experiment using RPMI media. Biosynthetic labelling and immunoprecipitation. Cells were starved for 15 min in DMEM (Cys-, Met-) or RPMI (Cys-, Met-), supplemented with 10% FCS and then labelled with [ 35 S]methionine/cysteine (276 mCi of Express 35 S protein labelling mix per 10 6 cells. Cells were washed and lysed in NP40 lysis buffer (25 mM Tris pH 7.4, 150 mM NaCl, 5 mM MgCl 2 , 0.5% NP-40). For immunoprecipitation, lysates were incubated with 20 ml of protein-G agarose and the antibody stated or immune serum. Monoclonal anti M2 antibody was used at 2.5 mg ml 21 . For all other immunoprecipitations, we used 1 ml of serum per ml of lysate. Incubations with antisera were performed for 3 h at 4 uC. The protein G Sepharose beads were washed three times in lysis buffer resuspended in SDS sample buffer. Where glycosidase treatment was required, digestions were performed following manufacturer's instructions (New England Biolabs), before addition of SDS sample buffer. To recover released virions form culture supernatants, the amount of supernatant used was normalized to the amount of radioactivity incorporated into cells. The adjusted volumes of supernatant were incubated with chicken red blood cells at a 1:50 dilution for three hours at 4 uC. The erythrocytes were washed by centrifugation (33) with PBS and lysed in NP40-containing lysis RESEARCH LETTER buffer. Immunoprecipitates and materials adsorbed onto chicken red blood cells were analysed by SDS-PAGE and autoradiography. Production of FluBI hybridoma. Spleen cells from FluBI;Rag2 2/2 mice were stimulated with 40 mg ml 21 LPS and 20ng ml 21 IL4 for 5 days, and were fused with NSObcl2 cells (a gift from B. Diamond) and selected in medium supplemented with 20% heat-inactivated FCS and hypoxanthine aminopterin thymidine (HAT) and grown in 10% CO 2 for 3 weeks, before transfer of positive clones to hypoxanthine thymidine (HT) supplemented medium containing 10% heat-inactivated FCS . Resulting hybridomas were screened for A/WSN/33 reactivity by ELISA using HRP-coupled anti-IgG2b or anti-Igk (Southern Biotech) secondary antibodies for detection. Statistics. Centre values are mean. P , 0.05 defined as significant. Standard twosided t-test was used throughout unless otherwise noted. Sample size was based on variability from pilot studies.
